|
1
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A, et al: The 2008 revision of the
World Health Organization (WHO) classification of myeloid neoplasms
and acute leukemia: Rationale and important changes. Blood.
114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bejar R, Levine R and Ebert BL: Unraveling
the molecular pathophysiology of myelodysplastic syndromes. J Clin
Oncol. 29:504–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bravo GM, Lee E, Merchan B, Kantarjian HM
and García-Manero G: Integrating genetics and epigenetics in
myelodysplastic syndromes: Advances in pathogenesis and disease
evolution. Br J Haematol. 166:646–659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cazzola M, Della Porta MG and Malcovati L:
The genetic basis of myelodysplasia and its clinical relevance.
Blood. 122:4021–4034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rocquain J, Carbuccia N, Trouplin V,
Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N,
Birnbaum D, et al: Combined mutations of ASXL1, CBL, FLT3, IDH1,
IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2, WT1 genes in
myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer.
10:401–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fenaux P, Haase D, Sanz GF, Santini V and
Buske C: ESMO Guidelines Working Group: Myelodysplastic syndromes:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 25 Suppl 3:iii57–iii69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
|
|
8
|
Malcovati L, Porta MG, Pascutto C,
Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L,
Maffioli M, Bernasconi P, et al: Prognostic factors and life
expectancy in myelodysplastic syndromes classified according to WHO
criteria: A basis for clinical decision making. J Clin Oncol.
23:7594–7603. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haferlach C, Bacher U, Haferlach T, Dicker
F, Alpermann T, Kern W and Schnittger S: The
inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by
alterations of the RUNX1, KRAS, NRAS, NF1 genes and mediates
adverse prognosis both in MDS and in AML A study in 39 cases of MDS
or AML. Leukemia. 25:874–877. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Odenike O and Le Beau MM: The dawn of the
molecular era of the myelodysplastic syndromes. N Engl J Med.
364:2545–2546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boultwood J, Perry J, Pellagatti A,
Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, Larrayoz
MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, et al: Frequent
mutation of the polycomb-associated gene ASXL1 in the
myelodysplastic syndromes and in acute myeloid leukemia. Leukemia.
24:1062–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thol F, Friesen I, Damm F, Yun H,
Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A,
Wichmann M, et al: Prognostic significance of ASXL1
mutations in patients with myelodysplastic syndromes. J Clin Oncol.
29:2499–2506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY,
Chen CY, Tseng MH, Huang CF, Lai YJ, Chiang YC, et al: Dynamics of
ASXL1 mutation and other associated genetic alterations
during disease progression in patients with primary myelodysplastic
syndrome. Blood Cancer J. 4:e1772014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paquette RL, Landaw EM, Pierre RV, Kahan
J, Lübbert M, Lazcano O, Isaac G, McCormick F and Koeffler HP:
N-ras mutations are associated with poor prognosis and increased
risk of leukemia in myelodysplastic syndrome. Blood. 82:590–599.
1993.PubMed/NCBI
|
|
16
|
Horiike S, Misawa S, Nakai H, Kaneko H,
Yokota S, Taniwaki M, Yamane Y, Inazawa J, Abe T and Kashima K:
N-ras mutation and karyotypic evolution are closely associated with
leukemic transformation in myelodysplastic syndrome. Leukemia.
8:1331–1336. 1994.PubMed/NCBI
|
|
17
|
Lai JL, Preudhomme C, Zandecki M, Flactif
M, Vanrumbeke M, Lepelley P, Wattel E and Fenaux P: Myelodysplastic
syndromes and acute myeloid leukemia with 17p deletion. An entity
characterized by specific dysgranulopoïesis and a high incidence of
P53 mutations. Leukemia. 9:370–381. 1995.PubMed/NCBI
|
|
18
|
Kaneko H, Misawa S, Horiike S, Nakai H and
Kashima K: TP53 mutations emerge at early phase of
myelodysplastic syndrome and are associated with complex
chromosomal abnormalities. Blood. 85:2189–2193. 1995.PubMed/NCBI
|
|
19
|
Simons A, Shaffer LG and Hastings RJ:
Cytogenetic Nomenclature: Changes in the ISCN 2013 compared to the
2009 edition. Cytogenet Genome Res. 141:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sambrook J, Fritsch EF and Maniatis T:
Molecular Cloning: A Laboratory Manual. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor; NY: 1989
|
|
21
|
Bejar R, Stevenson K, Abdel-Wahab O,
Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine
RL, Neuberg D, et al: Clinical effect of point mutations in
myelodysplastic syndromes. N Engl J Med. 364:2496–2506. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Itzykson R, Kosmider O and Fenaux P:
Somatic mutations and epigenetic abnormalities in myelodysplastic
syndromes. Best Pract Res Clin Haematol. 26:355–364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kulasekararaj AG, Smith AE, Mian SA,
Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C,
Ireland R, Czepulkowski B, et al: TP53 mutations in
myelodysplastic syndrome are strongly correlated with aberrations
of chromosome 5, and correlate with adverse prognosis. Br J
Haematol. 160:660–672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Devillier R, Mansat-De Mas V, Gelsi-Boyer
V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M,
Arnoulet C, et al: Role of ASXL1, TP53 mutations in the
molecular classification and prognosis of acute myeloid leucemias
with myelodysplasia-related changes. Oncotarget. 6:8388–8396. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Belickova M, Vesela J, Jonasova A, Pejsova
B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova
D, Lauermannova M, et al: TP53 mutation variant allele
frequency is a potential predictor for clinical outcome of patients
with lower-risk myelodysplastic syndromes. Oncotarget.
7:36266–36279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Andersen TI, Holm R, Nesland JM, Heimdal
KR, Ottestad L and Børresen AL: Prognostic significance of TP53
alterations in breast carcinoma. Br J Cancer. 68:540–548. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Machado-Neto JA, Traina F, De Melo Campos
P, Andreoli-Risso MF, Costa FF and Saad Olalla ST: Lack of
association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms
with clinical outcomes in myelodysplastic syndrome. Neoplasma.
59:530–535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McGraw KL, Zhang LM, Rollison DE, Basiorka
AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, et
al: The relationship of TP53 R72P polymorphism to disease
outcome and TP53 mutation in myelodysplastic syndromes.
Blood Cancer J. 5:e2912015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McGraw KL, Cluzeau T, Sallman DA, Basiorka
AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M,
Sokol L, et al: TP53, MDM2 single nucleotide polymorphisms
influence survival in non-del(5q) myelodysplastic syndromes.
Oncotarget. 6:34437–34445. 2015.PubMed/NCBI
|
|
30
|
Gelsi-Boyer V, Trouplin V, Roquain J,
Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet
C, Zerazhi H, et al: ASXL1 mutation is associated with poor
prognosis and acute transformation in chronic myelomonocytic
leukaemia. Br J Haematol. 151:365–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Kali A, Quintás-Cardama A, Luthra R,
Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E,
Faderl S, et al: Prognostic impact of RAS mutations in patients
with myelodysplastic syndrome. Am J Hematol. 88:365–369. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Della Porta MG, Malcovati L, Boveri E,
Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R,
Castello A, Magrini U, et al: Clinical relevance of bone marrow
fibrosis and CD34-positive cell clusters in primary myelodysplastic
syndromes. J Clin Oncol. 27:754–762. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Buesche G, Teoman H, Wilczak W, Ganser A,
Hecker H, Wilkens L, Göhring G, Schlegelberger B, Bock O, Georgii
A, et al: Marrow fibrosis predicts early fatal marrow failure in
patients with myelodysplastic syndromes. Leukemia. 22:313–322.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Malcovati L, Germing U, Kuendgen A, Della
Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B,
Bernasconi P, Knipp S, et al: Time-dependent prognostic scoring
system for predicting survival and leukemic evolution in
myelodysplastic syndromes. J Clin Oncol. 25:3503–3510. 2007.
View Article : Google Scholar : PubMed/NCBI
|
